nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.04.2014 | Original Paper

High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer

verfasst von: Hui Zhou, Jian-hua Chen, Jun Hu, Yong-zhong Luo, Fang Li, Ling Xiao, Mei-zuo Zhong

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Toll-like receptor 5 (TLR5) is a pattern recognition receptor and plays key roles in inflammatory responses against pathogen infection. Recent evidence suggests that TLR5 is expressed in a wide variety of tumors and exhibits either pro-tumor or anti-tumor activities. In this study, we explored expression of TLR5 in the context of non-small-cell lung cancer (NSCLC) and evaluated the effects of TLR5 signaling in NSCLC cells.

Methods

The lung carcinoma samples were collected from 113 patients diagnosed as NSCLC at Tumor Hospital of Xiangya School of Medicine from January 2005 to December 2008. Immunohistochemistry was performed for TLR5 and the protein expression score was quantified using an established scoring system. Kaplan–Meier survival curves were generated for disease-free survival (DFS) and overall survival (OS) in all patients. TLR5 expression levels were correlated with DFS and OS using univariate and multivariate Cox regression analysis. Expression and subcellular localization of TLR5 were analyzed in NSCLC cell lines including SPC-A1, A549, H1975, and H1299 cells. Activation of TLR5 signaling pathway by flagellin was characterized by western blotting. Effects of flagellin on NSCLC cell proliferation, anchorage-independent growth, migration, and invasion were analyzed by BrdU incorporation assay, soft agar colony formation assay, wound-healing migration assay, and transwell invasion assay, respectively.

Results

High expression of TLR5 was significantly associated with better prognosis in patients with NSCLC. We further demonstrated that activation of TLR5 by flagellin in NSCLC cells inhibited cell proliferation, migration, and invasion in vitro.

Conclusion

TLR5 may serve as a potential therapeutic target in NSCLC patients.

Akira S, Takeda K (2004) Toll-like receptor signalling. Nat Rev Immunol 4(7):499–511. doi:10.1038/nri1391 CrossRefPubMed

Badache A, Hynes NE (2001) Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61(1):383–391PubMed

Barton GM, Medzhitov R (2002) Toll-like receptors and their ligands. Curr Top Microbiol Immunol 270:81–92PubMed

Bill A, Schmitz A, Konig K, Heukamp LC, Hannam JS, Famulok M (2012) Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells. PLoS ONE 7(7):e41179. doi:10.1371/journal.pone.0041179 CrossRefPubMedCentralPubMed

Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D (2011) Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 71(7):2466–2475. doi:10.1158/0008-5472.CAN-10-1993 CrossRefPubMedCentralPubMed

Carney DN (2002) Lung cancer–time to move on from chemotherapy. N Engl J Med 346(2):126–128. doi:10.1056/NEJM200201103460211 CrossRefPubMed

Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean MC, Fridman WH, Damotte D, Sautes-Fridman C, Cremer I (2010) Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Investig 120(4):1285–1297. doi:10.1172/JCI36551 CrossRefPubMedCentralPubMed

Du Y, Ma C, Wang Z, Liu Z, Liu H, Wang T (2013) Nanog, a novel prognostic marker for lung cancer. Surg Oncol. doi:10.1016/j.suronc.2013.08.001

Ellis PM, Vandermeer R (2011) Delays in the diagnosis of lung cancer. J Thorac Dis 3(3):183–188. doi:10.3978/j.issn.2072-1439.2011.01.01 PubMedCentralPubMed

Farjah F, Flum DR, Varghese TK Jr, Symons RG, Wood DE (2009) Surgeon specialty and long-term survival after pulmonary resection for lung cancer. Ann Thorac Surg 87(4):995–1004. doi:10.1016/j.athoracsur.2008.12.030; discussion 1005–1006CrossRefPubMed

Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5):2315–2319. doi:10.1038/nprot.2006.339 CrossRefPubMed

Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, Aderem A (2001) The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410(6832):1099–1103. doi:10.1038/35074106 CrossRefPubMed

Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408(6813):740–745. doi:10.1038/35047123 CrossRefPubMed

Ishiguro H, Kishimoto T, Furuya M, Nagai Y, Watanabe T, Ishikura H (2005) Tumor-derived interleukin (IL)-6 induced anti-tumor effect in immune-compromised hosts. Cancer Immunol Immunother 54(12):1191–1199. doi:10.1007/s00262-005-0695-0 CrossRefPubMed

Iwamura C, Nakayama T (2008) Toll-like receptors in the respiratory system: their roles in inflammation. Curr Allergy Asthma Rep 8(1):7–13CrossRefPubMed

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics. CA Cancer J Clin 57(1):43–66CrossRefPubMed

Jiang BY, Zhang XC, Su J, Meng W, Yang XN, Yang JJ, Zhou Q, Chen ZY, Chen ZH, Xie Z, Chen SL, Wu YL (2013) BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol Cancer 12:61. doi:10.1186/1476-4598-12-61 CrossRefPubMedCentralPubMed

Kauppila JH, Mattila AE, Karttunen TJ, Salo T (2013a) Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer 108(3):638–643. doi:10.1038/bjc.2012.589 CrossRefPubMedCentralPubMed

Kauppila JH, Mattila AE, Karttunen TJ, Salo T (2013b) Toll-like receptor 5 and the emerging role of bacteria in carcinogenesis. Oncoimmunology 2(4):e23620. doi:10.4161/onci.23620 CrossRefPubMedCentralPubMed

Kim WY, Lee JW, Choi JJ, Choi CH, Kim TJ, Kim BG, Song SY, Bae DS (2008) Increased expression of Toll-like receptor 5 during progression of cervical neoplasia. Int J Gynecol Cancer 18(2):300–305. doi:10.1111/j.1525-1438.2007.01008.x CrossRefPubMed

Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM (2008) Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity. Cancer Lett 272(2):285–295. doi:10.1016/j.canlet.2008.07.016 CrossRefPubMed

Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M (2009) Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer Res 69(14):5893–5900. doi:10.1158/0008-5472.CAN-09-0755 CrossRefPubMedCentralPubMed

Pimentel-Nunes P, Afonso L, Lopes P, Roncon-Albuquerque R Jr, Goncalves N, Henrique R, Moreira-Dias L, Leite-Moreira AF, Dinis-Ribeiro M (2011) Increased expression of toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol Oncol Res 17(3):677–683. doi:10.1007/s12253-011-9368-9 CrossRefPubMed

Pinto A, Morello S, Sorrentino R (2011) Lung cancer and Toll-like receptors. Cancer Immunol Immunother 60(9):1211–1220. doi:10.1007/s00262-011-1057-8 CrossRefPubMed

Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B (1998) Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282(5396):2085–2088CrossRefPubMed

Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9(1):57–63. doi:10.1038/nrc2541 CrossRefPubMed

Rhee SH, Im E, Pothoulakis C (2008) Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135(2):518–528. doi:10.1053/j.gastro.2008.04.022 CrossRefPubMed

Rosell R, Bivona TG, Karachaliou N (2013) Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382(9893):720–731. doi:10.1016/S0140-6736(13)61715-8 CrossRefPubMed

Rusch VW, Asamura H, Watanabe H, Giroux DJ, Rami-Porta R, Goldstraw P (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4(5):568–577. doi:10.1097/JTO.0b013e3181a0d82e CrossRefPubMed

Samara KD, Antoniou KM, Karagiannis K, Margaritopoulos G, Lasithiotaki I, Koutala E, Siafakas NM (2012) Expression profiles of Toll-like receptors in non-small cell lung cancer and idiopathic pulmonary fibrosis. Int J Oncol 40(5):1397–1404. doi:10.3892/ijo 2012.1374PubMed

Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM (2007) Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer. FASEB J 21(13):3763–3770. doi:10.1096/fj.07-8832com CrossRefPubMed

Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140(6):805–820. doi:10.1016/j.cell.2010.01.022 CrossRefPubMed

Wang ZD, Qiao YL, Tian XF, Zhang XQ, Zhou SX, Liu HX, Chen Y (2012) Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis. Asian Pac J Cancer Prev 13(9):4763–4767CrossRefPubMed

Yamaji H, Iizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K, Tagawa M, Nakayama T, Fujisawa T (2004) Correlation between interleukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53(9):786–792. doi:10.1007/s00262-004-0533-9 CrossRefPubMed

Zhang J, Wu L, Qu JM (2011) Inhibited proliferation of human lung fibroblasts by LPS is through IL-6 and IL-8 release. Cytokine 54(3):289–295. doi:10.1016/j.cyto.2011.02.018 CrossRefPubMed

Zheng C, Sun YH, Ye XL, Chen HQ, Ji HB (2011) Establishment and characterization of primary lung cancer cell lines from Chinese population. Acta Pharmacol Sin 32(3):385–392. doi:10.1038/aps.2010.214 CrossRefPubMedCentralPubMed

Titel: High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer
verfasst von: Hui Zhou
Jian-hua Chen
Jun Hu
Yong-zhong Luo
Fang Li
Ling Xiao
Mei-zuo Zhong
Publikationsdatum: 01.04.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 4/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1616-4

Springer Medizin

High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Arginine-supplemented enteral nutrition

CEA/CA72-4 levels in peritoneal lavage fluid are predictive factors in patients with gastric carcinoma

GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells

Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism

Huge effect of arginine on survival in gastric cancer?

A systematic review on the safety and efficacy of yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie